[Efficacy of adalimumab in Behçet's disease. Description of 6 cases]. / Eficacia del adalimumab en la enfermedad de Behçet: descripción de 6 casos.
Reumatol Clin
; 7(4): 258-61, 2011.
Article
em Es
| MEDLINE
| ID: mdl-21794828
ABSTRACT
Behçet's disease (BD) is a systemic vasculitis, with a more aggressive course in young males. Orogenital ulcers, uveitis and cutaneous lesions are the most frequent manifestations. We analyzed the effects of adalimumab on six patients with BD pretreated with inmunosupressive therapy, two of whom had received infliximab. We observed a good clinical response in all patients. To date, after a mean follow-up of 26.8 months, patients continue receiving adalimumab, with good clinical control, no adverse effects have been reported with adalimumab.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Síndrome de Behçet
/
Fator de Necrose Tumoral alfa
/
Anticorpos Monoclonais Humanizados
Limite:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
Es
Ano de publicação:
2011
Tipo de documento:
Article